Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Amlodipine: Amlodipine is an approved medication for essential hypertension and is available widely
Dose - start with 5 mg once a day and may increase to 10 mg after four weeks at the
Sponsors
Associates for Cardiology Education and Research in Tamilnadu(ACERT)
Eligibility
Inclusion criteria
Inclusion criteria: Known cases of Essential hypertension ie. = 140/90 mm Hg as Office based recording that are naïve to beta-blocker, and CCB OR Known cases of Essential hypertension ie. = 140/90 mm Hg as Office based recording along with either T2DM, LVD and/or CKD that are naïve to beta-blocker, and CCB
Exclusion criteria
Exclusion criteria: known allergy to any of the Calcium channel blockers, history of active thyroid disease, CKD stage 3 or more, eGFR less than 30 ml/min/sq.m, Office BP more than 180/110 mm Hg, Secondary hypertension, type 1 diabetes mellitus, active liver disease, pregnant women, women planning pregnancy or lactating mother, person working in night shift, more than moderate valvular heart disease, pericardial disease, irregular rhythm like atrial fibrillation, unstable heart disease or heart failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Awake, 24 hour and Asleep Blood Pressure (SBP/DBP) between baseline and 8 weeks for the three arms using ABPM Change in office based Blood Pressure (SBP/DBP) between baseline and 4th, 8th week and 12th week for all the three arms Timepoint: 8 weeks for the three arms using ABPM Change in office based Blood Pressure (SBP/DBP) between baseline and 4th, 8th week and 12th week for all the three arms | — |
Secondary
| Measure | Time frame |
|---|---|
| change in dipping pattern between groupsTimepoint: 8 weeks;Changes in left ventricular (LV) mass index, LV Hypertrophy, LV global longitudinal strain, left atrial strainTimepoint: 12 weeks;changes in microalbuminuria/ albumin creatinine ratio between the three groupsTimepoint: 12 weeks;Proportions of patients achieving awake BP control of 135/85 mm Hg by ambulatory BPTimepoint: 8 weeks;proportions of patients achieving treatment induced adverse effectsTimepoint: 12 weeks;study the change in heart rate by ambulatory BP in the three groupsTimepoint: 8 weeks | — |
Countries
India
Contacts
Public ContactDPrabhakar
Ashwin Clinic
Outcome results
None listed